Aradigm Corporation

Aradigm — Technical Presentation (May 2017)

15 slides from Aradigm's technical presentation, May 22, 2017

  1. Slide 1: Inhaled Liposomal Ciprofloxacin in Non-CF Bronchiectasis: Results From ORBIT-3 and ORBIT-4

    Inhaled Liposomal Ciprofloxacin in Patients With Non-Cystic Fibrosis Bronchiectasis and Chronic Pseudomonas aeruginosa: Results From Two Parallel Phase III Trials (ORBIT-3 and -4) C.S. Haworth1, A. Wanner2, J. Froehlich3, T. O'Neal3, A. Davis4, I. Gonda3, A. O'Donnell5 1Cambridge Centre For Lung Inf

  2. Slide 2: Background

    Background Patients with non-cystic fibrosis bronchiectasis (NCFBE) and Pseudomonas aeruginosa (PA) infection have a greater risk of: Frequent pulmonary exacerbations (PEs) Hospital admissions Decreased quality of life Higher mortality ARD-3150 is a once-daily inhaled antibiotic containing liposome

  3. Slide 3: Background: ORBIT-3 and ORBIT-4 trials

    Background ORBIT-3 and ORBIT-4 were identical, 48-week, multinational, randomized, double-blind, placebo-controlled phase III trials in patients with NCFBE and chronic PA lung infections, followed by a 28-day open-label extension These trials were designed to evaluate the efficacy of once-daily ARD-

  4. Slide 4: ORBIT-3 & ORBIT-4 Clinical Site Countries

    ORBIT-3 & ORBIT-4 Clinical Site Countries

  5. Slide 5: Methods – Patients

    Methods – Patients Patients ≥18 years with a confirmed diagnosis of NCFBE by CT and at least 2 PEs treated with antibiotics in the preceding 12 months CT, computed tomography; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; NTM, non-tuberculosis mycobacterial

  6. Slide 6: Study Design – ORBIT-3 and ORBIT-4

    Study Design – ORBIT-3 and ORBIT-4 CFU, colony forming units of P. aeruginosa, determined from sputum analysis QD, once daily Nebulized ARD-3150 or placebo were administered once daily for 6 cycles of 28 days on treatment, separated by 28 days off treatment, during the 48-week double-blind phase Pat

  7. Slide 7: Protocol Definitions for Determining PE

    Protocol Definitions for Determining PE *O’Donnell et al. 1998 FVC, forced vital capacity Pulmonary Exacerbation Blinded Adjudication Committee Blinded adjudication of PEs when the investigator’s assessment was in disagreement with the protocol definitions New/change in signs or symptoms: Change in

  8. Slide 8: Baseline Demographics

    Baseline Demographics ORBIT-3 ORBIT-4 ARD-3150 (n=183) Placebo (n=95) ARD-3150 (n=206) Placebo (n=98) Age (years), mean ± SD 64 ± 14 67 ± 11 63 ± 13 64 ± 13 Race, n (%) White Asian Black or African American Other / Not Reported Ethnicity, n (%) Hispanic or Latino 161 (88) 15 (8) 3 (2) 4 (2) 6 (3) 89

  9. Slide 9: Disposition / Withdrawals From Study

    Disposition / Withdrawals From Study ORBIT-3 Screened = 514 ORBIT-4 Screened = 533 ARD-3150 Placebo ARD-3150 Placebo Randomized, n 183 95 206 98 Withdrawn, n (%) 41 (22) 18 (19) 28 (14) 17 (17) Reason for withdrawal, n (%) Adverse event 16 (9) 3 (3) 5 (2) 4 (4) Per-protocol defined PE 1 (0.5) 0 0 0

  10. Slide 10: Time to First PE - all severities

    Time to First PE - all severities Hazard Ratio Lower Confidence Limit Upper Confidence Limit 0.82 0.65 1.02 0.72 0.53 0.97 0.99 0.71 1.38 Stratified unweighted log-rank test Stratification factors: sex and previous number of exacerbations in the past 12 months prior to randomization ARD-3150 signifi

  11. Slide 11: Time to First Moderate or Severe PE

    Time to First Moderate or Severe PE ARD-3150 significantly increased median time to first PE that required treatment with antibiotics in ORBIT-4 and the pooled data analysis Hazard Ratio Lower Confidence Limit Upper Confidence Limit 0.74 0.59 0.94 0.66 0.48 0.91 0.88 0.62 1.24 Stratified unweighted

  12. Slide 12: Frequency of all PEs

    Frequency of all PEs ARD-3150 was associated with a significant reduction in the point estimate of the annual frequency of PEs in ORBIT-4 and the pooled analysis Stratified negative binomial regression; stratified by sex and prior PEs Relative Risk Lower Confidence Limit Upper Confidence Limit 0.73

  13. Slide 13: Change in Sputum Density of P. aeruginosa

    Change in Sputum Density of P. aeruginosa ARD-3150 significantly reduced sputum density of P. aeruginosa while on treatment over the 48-week period With the exception of 1 visit in ORBIT-3, statistically significant reductions were observed at the end of every on-treatment period throughout the cour

  14. Slide 14: Adverse Events

    Adverse Events * No deaths were considered related to study drug AE, adverse event; DLCO, diffusing capacity of the lungs for carbon monoxide; TEAE, treatment-emergent adverse event; SAE, serious adverse event N (%) ORBIT-3 ORBIT-4 ARD-3150 (N=183) Placebo (N=95) ARD-3150 (N=206) Placebo (N=98) TEAE

  15. Slide 15: Conclusions

    Conclusions In patients with NCFBE, PA and ≥2 exacerbations in the year preceding enrollment, ARD-3150: Not significant (NS); ü denotes statistical significance ARD-3150 was well tolerated with a similar adverse event profile to placebo ORBIT-3 ORBIT-4 POOLED ANALYSIS Increased the median time to fi

Aradigm — Technical Presentation (May 2017) on 6ix